Global Autoimmune Disease Testing Market Likely to reaching up to USD 9 Billion by 2035
An extensive study of propelling opportunities in, “Autoimmune Disease Testing Market Size, Share, Growth Opportunity Analysis Report by Test Type (Antinuclear Antibody (ANA) Tests, Autoantibody Tests, C-reactive Protein (CRP) Tests, Erythrocyte Sedimentation Rate (ESR) Tests, Rheumatoid Factor (RF) Tests, Immunologic Tests, Enzyme-linked Immunosorbent Assay (ELISA), Others), Disease Type, Product Type, Technology, Sample Type, Sample Type, End User, and Geography (North America, Europe, Asia Pacific, Middle East, Africa, and South America) – Global Industry Data, Trends, and Forecasts, 2025–2035” A comprehensive report of growing market landscapes in the autoimmune disease testing sector uncovering key growth drivers including niche market leadership, technology-enabled distribution, and increasing consumer needs supporting autoimmune disease testing potential to scale globally.
Global Autoimmune Disease Testing Market Forecast 2035:
According to the report, the autoimmune disease testing market is anticipated to grow from USD 4.6 Billion in 2025 to USD 8.9 Billion in 2035 at a CAGR of 6.8% during the forecast. The market for autoimmune disease testing is quietly transforming fueled by an increase in chronic immune conditions, delayed diagnosis, and the opportunity for precision diagnostics. The introduction of new autoantibody multiplex testing, machine-learning-based analysis, and multi-omics technologies is going to enable detection of autoimmune disorder even earlier than is currently possible with existing methods. In early 2025, we worked with a joint lab in Scandinavia to run an AI-supported diagnostic workflow for systemic lupus and rare autoimmune syndromes with a 30% improved early detection rate.
Meanwhile in Canada and parts of the U.S.; patient advocacy organizations are teaming with mobile testing services and community health networks to develop low-cost research opportunities with underserved populations who have historically been undiagnosed. Further, it is discussed that awareness, accessibility to tests and cost are a factor in underserved places with limited health care access.
Moreover, autoimmune diagnostics are heading towards faster, more accurate, and less stress full diagnostic solutions for patients. The challenge will be for biotech innovation to be married with affordability, patient education, integrated pathways of care, and for early diagnosis to be the norm, not the exception, in a diagnosis journey that has been historically impaired by delays and complexity.
“Key Driver, Restraint, and Growth Opportunity Defining the Global Autoimmune Disease Testing Market
The prevalence of autoimmune diseases, such as rheumatoid arthritis, lupus, and type 1 diabetes, is the most significant market growth factor in the autoimmune disease testing market. As autoimmune disorders become more well-known, and, more generally, chronic and debilitating diseases in general, the need for early diagnostic testing is expanding, especially in older individuals, however more so with undiagnosed health complaints in younger individuals. This urgency drives health systems and diagnostic companies to enhance screening accuracy and screening opportunities.
A key constraint for the future of the market is the complexity of the diagnosis and high-cost of testing. Autoimmune diseases typically present with non-specific and overlapping complaints, requiring multiple, often expensive tests to establish a diagnosis. Moreover, lengthy diagnostic delays upwards of years are frequent, even in the most advanced healthcare systems, thus further eroding the accuracy of the testing that follows. Lastly, restrictions on advanced diagnostic tests in several developing regions, creates additional barriers to market penetration and expansion.
The largest opportunity is the adoption of the use of AI-enabled diagnostics and multi-omics testing (genomics, proteomics, etc.) to quickly and accurately identify disease biomarkers. This not only assists in the early detection of disease, however is also leverages personalized medicine strategies and includes the growth of mobile units, and point-of-care (POC) diagnostics used in rural and poor regions.
"Impact of Global Tariff Policies on the Global Autoimmune Disease Testing Market Growth and Strategy"
In the market for testing of autoimmune diseases, global tariffs on diagnostic devices, reagents and laboratory equipment can increase operating costs especially for laboratories in third world countries that depend on imports to completely furnish their laboratories.
Further, tariffs are able to inhibit market growth in price sensitive geographies and diminish access to accurate, quality testing. Attributed to which, organizations are concentrating on the localization of manufacturing, building regional supply chain alliances with other companies, and creating affordable test kits that can be produced closer to the first point of use. Uncertainty from tariffs is also encouraging organizations to strategically invest in automated and compact testing platforms that decrease the number of imported components and related tariffs.
Surge in Global Autoimmune Disease Testing Market
"Global Autoimmune Disease Burden, Diagnostic Advancements, and Personalized Medicine Propel the Expanding Autoimmune Disease Testing Market"
Regional Analysis of Global Autoimmune Disease Testing Market
Key players operating in the autoimmune disease testing market include Abbott Laboratories, Beckman Coulter, Inc., bioMérieux SA, Bio-Rad Laboratories, Inc., Danaher Corporation, EUROIMMUN AG, Exagen Inc., F. Hoffmann-La Roche Ltd, Grifols, S.A., Hologic, Inc., Inova Diagnostics, Inc., Myriad Genetics, Inc., ORGENTEC Diagnostika GmbH, Phadia AB (a Thermo Fisher brand), Quest Diagnostics Incorporated, Siemens Healthineers, SRL Diagnostics, Thermo Fisher Scientific Inc., Trinity Biotech plc, Werfen Life Group, and other key players contributing to market growth through innovation, strategic partnerships, and global expansion.
The Autoimmune Disease Testing Market has been segmented as follows:
Autoimmune Disease Testing Market Analysis, by Test Type
Autoimmune Disease Testing Market Analysis, by Disease Type
Autoimmune Disease Testing Market Analysis, by Product Type
Autoimmune Disease Testing Market Analysis, by Technology
Autoimmune Disease Testing Market Analysis, by Sample Type
Autoimmune Disease Testing Market Analysis, by Method Type
Autoimmune Disease Testing Market Analysis, by End User
Autoimmune Disease Testing Market Analysis, by Region
About Us
MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.
We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.
Contact US
USA Address:
800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.
+1(302)303-2617
India Address:
3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.
Table of Contents
Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography
We will customise the research for you, in case the report listed above does not meet your requirements.
Get 10% Free Customisation